Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	November 4, 2010 June 15, 2012; July 7, 2022

VIBATIV® (telavancin)

LENGTH OF AUTHORIZATION:

- Up to 14 days for complicated skin and skin structure infection (cSSSI)
- Up to 21 days for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)

REVIEW CRITERIA:

- Patient must be ≥ 18 years of age.
- Patient must have a diagnosis of:
  - cSSSI caused by susceptible isolates of the following gram-positive bacteria: *Staphylococcus aureus* (including methicillin-resistant & methicillin-susceptible isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus anginosus* group (includes *S. anginosus*, *S. intermedius*, & *S. constellatus*), or *Enterococcus faecalis* (vancomycin-susceptible isolates only); **OR**
  - HABP/VABP caused by susceptible isolates of *Staphylococcus aureus* (both methicillin-resistant & methicillin-susceptible isolates).
- Patient must have documented trial and failure with vancomycin for the current active infection; **OR**
- Patient must have documented contraindication or intolerance to treatment with vancomycin.
- A recent (within past 60 days) culture and sensitivity (C&S) must be submitted.
- There are no available data on Vibativ use in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

DOSING AND ADMINISTRATION:

- Refer to product labeling at https://www.accessdata.fda.gov/scripts/cder/daf/
- Available as: 250 mg and 750 mg powder for injection in a single-dose vial.